The firm’s $48bn PE business is unlikely to see a ‘wave’ of realisations given market conditions, president Tony James admitted, as Q2 net income fell by 75% from last year's figure.
3 min read · 14 January 2013
The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.
2 min read · 14 January 2013
The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.
2 min read · 14 January 2013
The retirement system’s $21bn private equity portfolio generated a 5.9% return last fiscal year, outperforming its overall portfolio by 4.1%.
1 min read · 14 January 2013
The firm's buyout group will acquire listed pharmaceutical company Par Pharmaceutical. TPG also has investments in several pharmaceutical companies through its TPG Biotech portfolio.
2 min read · 15 January 2013
Summit Partners is less than $33m away from a $350m target on its credit fund, which launched last year.
1 min read · 14 January 2013
Summit Partners is less than $33m away from a $350m target on its credit fund, which launched last year.
1 min read · 14 January 2013
Former Credit Suisse Asset Management executive Mark Bourgeois will replace Atlantic-Pacific Capital’s founder, James Manley, as CEO. Manley (pictured) will remain chairman.
1 min read · 14 January 2013
Gatekeeper Altius Associates has held a first close for its second fund of funds on $50m after three months on the fundraising trail.
1 min read · 14 January 2013
The shortcomings in US infrastructure have received much attention. Jay Brown (pictured) and Robin Priest argue that a modest channeling of income tax revenue could be a big step towards addressing the problem
5 min read · 15 January 2013
